Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Exclusion Criteria

• •1. Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China
• •2. Active ocular inflammation or suspected / active ocular infection in either eye
• •3. Received any other anti-VEGF treatment after faricimab
• •4. Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye
• •5. Any participation in any other clinical trials currently
• •6. Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection